Improvement in analysis and reporting results of osteoarthritis (OA) clinical trials has been
recently obtained because of harmonization and standardization of the selection of outcome …

… CTGF, connective tissue growth factor; PDGF, platelet-derived growth factor; TGF-β, transforming
growth factor-β; T H 2, type 2 T helper cell T H 17, type 17 T helper cell; VEGF, vascular …

The aim of this review is to discuss the potential usefulness of novel advances in the class
of biochemical markers, neo-epitopes. Neo-epitopes are post-translational modifications (…

… was calculated as the total incremental costs incurred on day ‘t’ (TIC t ) divided by the … at
any day ‘t’ was measured as the difference between the AAC t for patients with and the AAC t for …

Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad
effects on immune and inflammatory responses. Our aim was to assess the therapeutic …

Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative
had developed two sets of responder criteria to present the results of changes after treatment …

Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an
excellent target for clinical immunosuppression. We report the development of a specific, …

… IL-6 is involved in multiple immunologic processes such as T cell activation, B cell proliferation,
initiation of acute-phase protein, and stimulation of hematopoietic precursor cell growth, …

… T Woodworth9, … objective of the AMBITION (Actemra versus Methotrexate double-Blind
Investigative Trial InmONotherapy) study was to compare the efficacy and safety of tocilizumab …

… to ten patients to gauge the contribution of activated T cells to the disease. Four patients …
and CD8 + T cells, suggesting a primary immunological basis for this widespread disorder. …